We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Broad-Spectrum Antibiotics Ineffective as Initial Pneumonia Treatment

By HospiMedica International staff writers
Posted on 09 Mar 2020
A new study shows that hospitalized pneumonia patients prescribed antibiotics that target methicillin-resistant Staphylococcus aureus (MRSA) fare no better than standard medical care. More...


Researchers at the Veterans Affairs Salt Lake City Health Care System (UT, USA) and the University of Utah (UU; Salt Lake City, USA) conducted a retrospective cohort study involving 88,605 hospitalized patients (median age 70 years, predominantly men) who received either anti-MRSA or standard therapy for community-onset pneumonia. The main outcomes were 30-day all-cause mortality, after adjustment for patient comorbidities, vital signs, and laboratory results. Secondary outcomes included kidney injury and secondary infections with Clostridioides difficile, vancomycin-resistant Enterococcus species, or gram-negative bacilli.

The results revealed no discernable benefit of anti-MRSA treatment in addition to standard treatment. In fact, anti-MRSA treatment was associated with a 40 % higher risk of dying within 30 days of discharge, perhaps due to potentially severe side effects of vancomycin, including increased incidence of kidney failure and secondary infections. The researchers also observed that as doctors became more aware of MRSA infection in the lungs, they tended to use anti-MRSA drugs as initial treatment, despite the fact that MRSA only accounts for about 2% of pneumonia cases. The study was published on February 17, 2020, in JAMA Internal Medicine.

“In the absence of better tests to identify MRSA as a potential pathogen causing the disease, using anti-MRSA therapies does not seem to offer any advantage over standard treatment therapy,” said lead author Barbara Ellen Jones, MD, MSc, of UU. “Under these circumstances, it may be safer for patients if physicians to stick to standard antibiotic treatments for a couple of days to see how patients are doing, rather than leaping into anti-MRSA therapy right off the bat.”

Pneumonia is the eighth leading cause of death in the United States, accounting for more than one million hospitalizations and about 50,000 deaths each year. It can be caused by viruses, fungi, and bacteria, including MRSA.

Related Links:
Veterans Affairs Salt Lake City Health Care System
University of Utah



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.